Lyme disease is a growing problem with no approved preventive solution1,2
Woman leaning against a tree.

Lyme Disease

Lyme disease is the most common vector-borne disease in the United States and, according to the Centers for Disease Control and Prevention, the areas where it is common are expanding.1,2

Person icon

More than 30 million Americans are at high or moderate risk of contracting Lyme disease.2

Health icon

Approximately 300,000-400,000 people are diagnosed with Lyme disease in the United States each year.2

Lyme disease is spread through blacklegged deer ticks3

Infected ticks are commonly found in the northeastern, mid-Atlantic, and northern central United States and cause Lyme disease by transmitting the bacterium Borrelia burgdorferi. The majority of humans are infected through the bite of immature ticks called nymphs, which are so small that they typically go undetected. In most cases, the tick must be attached for 36 to 48 hours or more before the Lyme disease bacterium can be transmitted.3

Blacklegged deer tick.
Patient in pain.

Lyme disease signs and symptoms are diverse and can be devastating4

Typical symptoms of early Lyme disease include4:

  • Erythema migrans rash
  • Fever
  • Chills
  • Swollen lymph nodes
  • Headache
  • Fatigue
  • Muscle and joint aches

When left untreated, symptoms worsen and can include4:

  • Facial palsy
  • Irregular heartbeat
  • Episodes of dizziness
  • Shortness of breath
  • Nerve pain
  • Joint pain and swelling
  • Inflammation of the nervous system
  • Severe headache and neck stiffness
  • Intermittent pain in tendons, muscles, joints, and bones

Lyme disease creates a serious financial burden5

Untreated Lyme disease costs the US healthcare system up to $1.3 billion a year5

There is currently no FDA-approved pharmacological option for preventing Lyme disease2

Learn about TP-05

1. Recent surveillance data. US Centers for Disease Control and Prevention. Accessed August 11, 2023. 2. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. Tarsus Pharmaceuticals, Inc. Press release. June 16, 2021. Accessed August 11, 2023. 3. Transmission. US Centers for Disease Control and Prevention. Accessed August 11, 2023. 4. Signs and symptoms of untreated Lyme disease. US Centers for Disease Control and Prevention. Accessed August 11, 2023. 5. Lyme disease costs up to $1.3 billion per year to treat, study finds. Johns Hopkins Bloomberg School of Public Health. Published February 5, 2015. Accessed August 11, 2023.

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.